Aspen Pharmacare Holdings Limited (APNHF) Q2 2025 Earnings Call Transcript

2025-03-04 14:20:16 ET

Aspen Pharmacare Holdings Limited (APNHF)

Q2 2025 Results Conference Call

March 04, 2025 01:30 AM ET

Company Participants

Sibongakonke Nkosi - Investor Relations

Stephen Saad - Group Chief Executive Officer

Sean Capazorio - Group Chief Financial Officer

Presentation

Sibongakonke Nkosi

Good morning. A very warm welcome to everyone joining us in person, online for Aspen's 2025 Interim Results Presentation. To kick things off, we'll hear from Stephen, our Group CEO, will take us and give us an overview of our performance. Following that, we'll have Sean, our Group CFO, who'll run us through the financial review. Stephen will then return to discuss our strategy, prospects and guidance. [Operator Instructions]

With that, I'll now hand over to Stephen. Stephen, over to you.

Stephen Saad

Good morning, everyone, and thank you for those that are here live, and those that are online, welcome too. Interesting time and juncture that we've reached as Aspen. I'm trying to think it might have been 2 or 3 presentations ago, we gave you a presentation with green lines and red lines and the red with the headwinds and the green is where we hope to get to this point and financial year '25 was an important year for us. All the red lines came true.

So all the headwinds were there and as is life, that will come true. But I'm also happy to tell you that our green lines that also have come true. So, where we stand today, strategically, we have a Commercial Pharma business that has been derisked, derisked from a -- let me see, if we get this thing going here, sorry -- trying to keep to the script, but I'm not very good at that. But derisked from a perspective of that we've dealt with China VBP. We've dealt with the issues within Russia. And so you're starting to see the base growth that we were talking about historically and without China and then we also said so Commercial Pharma is about derisking and getting the organic base right.

In Manufacturing, we've got -- we had a couple of key objectives here. One was to resolve heparin and 2 was to start building on finished dose form sterile contracts. I think we've achieved all of that. The heparin business, as you know, about this time last year, we managed to turn it into a toll model. So we weren't exposed to commodity risks. And the sterile contracts, as you can see, are building year-on-year. If I stand here today and tell you what are we really focused on, I think we've -- our key objectives going forward are really twofold: one, to keep building on the sterile contracts, particularly our South African contracts. We really need to deliver on those and it's getting really close now and of course, the opportunities around the GLP-1 space, both commercially and manufacturing-wise....

Read the full article on Seeking Alpha

For further details see: